trending Market Intelligence /marketintelligence/en/news-insights/trending/sf0hkvlf1k_drmitdsaz5a2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Cardiome Pharma launches skin drug in Germany

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles

Energy

Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018


Cardiome Pharma launches skin drug in Germany

Cardiome Pharma Corp. launched the Xydalba skin treatment ahead of schedule in Germany.

The drug is approved by the European Medicines Agency to treat adults with acute bacterial skin and skin structure infections, or ABSSSI. It has already been launched in the U.K.

The drug is planned for further launch in other European countries. The German ABSSSI hospital market is valued at $123 million, according to Datamonitor.